Drug intelligence / Profile preview

ARS02C

Development stage: Unknown
Lead developer: ARScience Biotherapeutics
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

**ARS02C** is an ARScience Biotherapeutics preclinical, subcutaneous low-dose recombinant interleukin-2 combination program intended to support regulatory T-cell based immunomodulation across multiple therapeutic areas. Low-dose IL-2 is designed to preferentially stimulate high-affinity IL-2 receptor signaling on regulatory T cells, promoting their expansion and immunoregulatory function; the identity of the additional combination component or components has not been publicly disclosed. ([biobase.whitefordresearch.com](https://biobase.whitefordresearch.com/companies/arscience-biotherapeutics))

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on ARS02C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARS02C.

Explore the full profile